Table 1.
Associations between levels of CAFs, Schwannian Stroma, MVP and clinical risk factors in the CMH cohort
| Characteristic | CAFs Low | CAFs High | Total | P |
|---|---|---|---|---|
|
| ||||
| Diagnosis | <0.001 | |||
| NB(A+B+C) | 9 (21%) | 33 (78%) | 42 | |
| A. Undifferentiated NB | 1 (20%) | 4 (80%) | 5 | |
| B. Poorly differentiated NB | 2 (14%) | 12 (86%) | 14 | |
| C. Differentiating NB | 6 (26%) | 17 (74%) | 23 | |
| Nodular GNB | 0 (0%) | 4 (100%) | 4 | |
| Intermixed GNB | 5 (71%) | 2 (29%) | 7 | |
| GNR | 7 (100%) | 0 (0%) | 7 | |
|
| ||||
| Schwannian Stroma | <0.001 | |||
| NB+nodular GNB, SS-poor | 9 (20%) | 37 (80%) | 46 | |
| Intermixed GNB+GNR, SS-rich | 12 (86%) | 2 (14%) | 14 | |
|
| ||||
| Microvascular Proliferation | <0.001 | |||
| NB+intermixed GNB+GNR, no MVP | 13 (60%) | 9 (40%) | 22 | |
| NB and nodular GNB with MVP | 5 (16%) | 33 (84%) | 38 | |
|
| ||||
| Age * | 0.51 | |||
| < 12 months | 4 (21%) | 15 (79%) | 19 | |
| ≥ 12 months | 10 (29%) | 24 (71%) | 34 | |
|
| ||||
| Risk Group * | 0.88 | |||
| High-Risk | 3 (20%) | 12 (80%) | 15 | |
| Non High-Risk | 7 (28%) | 18 (72%) | 25 | |
|
| ||||
| MYCN * | 0.75 | |||
| Amplified | 2 (22%) | 7 (78%) | 9 | |
| Non-amplified | 11 (28%) | 29 (72%) | 40 | |
|
| ||||
| Histology * | 0.18 | |||
| Unfavorable | 3 (13%) | 20 (86%) | 23 | |
| Favorable | 8 (29%) | 20 (71%) | 28 | |
|
| ||||
| Stage * | 0.49 | |||
| 1, 2, 3 , 4S | 10 (29%) | 24 (70%) | 34 | |
| 4 | 3 (20%) | 12 (80%) | 15 | |
|
| ||||
| Survival * | 0.89 | |||
| Dead | 2 (29%) | 5 (71%) | 7 | |
| Alive | 12 (26%) | 34 (74%) | 46 | |
NB: neuroblastoma; GNB: ganglioneuroblastoma; GNR:ganglioneuroma; SS: Schwannian Stroma
*
only NB+GNB